ReviewFrontiers in oncology2026
De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potential treatment-related side effects of radiotherapy for head and neck squamous cell carcinoma are substantial and affect long-term quality-of-life. This narrative review discusses de-escalation strategies aimed at reducing side effects without compromising oncologic outcomes. Four categories of radiotherapy de-escalation strategies are discussed. First, elective neck dose- and volume de-escalation have shown very low rates of isolated regional recurrence in prospective and retrospective cohorts, however clinical benefits in unselected patient cohorts remain modest. Personalized dose and volume-de-escalation is currently under investigation, e.g. in risk-adapted elective neck volume-reduction based on lymphatic drainage mapping. Second, in HPV-related oropharyngeal cancer, unselected de-escalation strategies seemed to be inferior in terms of cure and survival, however risk-stratified approaches for post-operative radiotherapy or response-guided radiotherapy after neoadjuvant systemic therapy are promising, especially in intermediate-risk patients. Phase III randomized trials are currently recruiting patients in this matter. Third, adaptive radiotherapy can correct anatomical changes during treatment, but prospective trials are now needed to demonstrate its clinical benefits and safety in case of reducing volumes of targets. Fourth, proton therapy offers substantial dosimetric sparing and reduced acute toxicity in oropharynx, nasopharynx and nasal cavity and paranasal sinus cancer patients, however broad implementation is still limited by cost and access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.